Rare / orphan disease drugs

Discover the landscape of Rare / orphan disease drugs in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Rare / orphan disease drugs, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

FDA Approves Viatris's RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label
CompanyDrug

FDA Approves Viatris’s RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label

Viatris Inc. (NASDAQ: VTRS) announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is already…

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients
CompanyDrug

Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients

Sanofi's Rilzabrutinib Shows Promise in IgG4-Related Disease Trial
CompanyDrug

Sanofi’s Rilzabrutinib Shows Promise in IgG4-Related Disease Trial

Biogen Launches Qalsody in China for SOD1-ALS Treatment
CompanyDrug

Biogen Launches Qalsody in China for SOD1-ALS Treatment

Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease
CompanyDrug

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease

Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline
CompanyDeals

Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline

R&B Biotech Receives FDA Approval for ZS805 Gene Therapy in Fabry Disease
CompanyDrug

R&B Biotech Receives FDA Approval for ZS805 Gene Therapy in Fabry Disease

Novartis' Fabhalta Approved for Previously Treated PNH Patients in China
CompanyDrug

Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China

RemeGen's Telitacicept Approved for Myasthenia Gravis in China
CompanyDrug

RemeGen’s Telitacicept Approved for Myasthenia Gravis in China

Show More